Introduction: Korean government have launched asthma quality evaluation program to improve the quality of the management protocol and prognosis of asthma since 2013. We aimed to reveal the impact of this program on prescription pattern, medical utility, medical cost, and death in asthma patients in Korea. Methods: We used claims data in the national medical insurance review system provided by the Health Insurance Review and Assessment Service of Korea from July 1, 2013 to June 30, 2017. A definition of asthma was made when subjects visit hospital for asthma as the major or the first minor diagnosis at least two times. Results: Among 4.3 million asthma subjects, about 0.8 million asthma subjects (study group) were assessed by the asthma quality evaluation program annually. In asthma subjects who were not assessed by the program (control group), pulmonary function test (PFT) conduction rate (from 6.3% to 8.0%, 27.0% increase) and inhaled corticosteroid (ICS) prescription rate (from 8.1% to 10.2%, 25.9% increase in ICS) were much improved for 4 years. In study group, similar pattern was shown (from 23.9% to 31.3%, 37.6% increase in PFT; from 27.8% to 36.7%, 31.5% increase in ICS), however the baseline value was better than that in control group. In control group, admission rate, medical cost, and death rate (from 0.77%/yr to 0.98%/yr, 27.3% increase) were increased for 4 years. However, increasing rate of admission rate and medical cost were much less, and death rate (from 1.58%/yr to 1.52%/y, 3.8% decrease) was diminished in study group. Conclusion: The asthma quality evaluation program conducted by Korean government leads to improve management protocol regardless of group. Moreover, this program resulted improvement of death rate in study group.